Compare Crocs, Inc. (CROX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs TG Therapeutics Inc — how do they compare? Crocs, Inc. trades at $130.4 (market cap $6.31B), while TG Therapeutics Inc trades at $49.58 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Crocs, Inc. is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CROX | TGTX | |
|---|---|---|
Market Cap | $6.31B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $59.06 |
52-Week Low | $73.39 | $26.94 |
Enterprise Value | $7.83B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.39, down 5.65% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 57.47% gross margin and 42.3% ROE, but faces headwinds from a net loss in 2025 and negative sentiment around tax practices. Recent news highlights a raised full-year outlook post-Q2 results, though near-term guidance disappointed investors.
The outlook is mixed: valuation ratios like P/E of 11.69 appear attractive, and analyst consensus leans bullish with a $140.43 price target. However, risks include tax scrutiny, HEYDUDE brand weakness, and volatile cash flows. Upside depends on execution of DTC and international growth strategies amid competitive pressures.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
